Skip to main content
OpenTrials
Completed

NCT Number: NCT02297243

Sinopsys Lacrimal Stent Indicated for Sinus Irrigation

The purpose of this study is to collect preliminary clinical data related to the safety and performance of the Sinopsys Lacrimal Stent.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Stanford University, Stanford, California, United States

Loading trial locations.

About this study

For purposes of this clinical study, the Sinopsys Lacrimal Stent is intended to provide a means of administering saline sinus irrigation via a transcaruncular-ethmoid sinus access in patients with moderate to severe chronic rhinosinusitis with ethmoid involvement. The purpose of the administration of saline irrigation is to reduce the intensity of symptoms of chronic rhinosinusitis in this patient population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The Investigator has determined that the potential study subject has moderate to severe chronic rhinosinusitis with ethmoid involvement and has followed at least twelve (12) weeks of appropriate medical therapy prior to enrollment
  • Age ≥ 22 years
  • The potential study subject meets the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) criteria for chronic rhinosinusitis 12 weeks or longer of two or more of the following signs and symptoms:
  • Mucopurulent drainage (anterior, posterior, or both)
  • Nasal obstruction (congestion)
  • Facial pain-pressure-fullness, or
  • Decreased sense of smell

AND inflammation is documented by one or more of the following findings:

  • Purulent (not clear) mucus or edema in the middle meatus or ethmoid region
  • Polyps in nasal cavity or the middle meatus, and/or
  • Radiographic imaging showing inflammation of the paranasal sinuses
  • SNOT-20 total score ≥ 41
  • CT scan (coronal view) confirms inflammation / involvement of the ethmoid sinuses
  • CT scan (coronal view) confirms depth of olfactory fossa is Keros classification 1 or 2.

Exclusion criteria

  • Sinus opacification score of ≤ 8 or ≥ 18 measured using the CT derived Lund -- Mackay scoring system
  • Isolated sinus disease evident on CT scan that would be unlikely to respond to target ethmoid treatment (e.g., isolated sphenoid or frontal disease)
  • Severe polyposis defined as Grade III or Grade IV polyposis using the adapted scale from Meltzer, 2006.
  • Prior ocular and/or sinus surgery for CRS
  • CT scan (coronal view) shows depth of olfactory fossa is Keros classification 3.
  • Prior surgical history, physical exam, nasal endoscopy and/or imaging studies suggest significant distortion of the craniofacial anatomy thus prohibiting adequate placement of the SLS
  • Presence of a sinonasal encepholocele as determined by CT scan
  • Presence of active HEENT infection including acute dacryocystitis
  • Febrile illness within 2 weeks and/or active pus from nose
  • Any sign of active ophthalmic disease, infection, or inflammation including the presence of severe ocular surface inflammatory disease or signs and symptoms of "dry eye disease" as determined by physical exam which could be exacerbated by the presence of the device
  • Current use of topical medications for the eye to treat an active ophthalmic disease
  • HbA1c level of ≥ 7.5% at the time of screening, current chemotherapy, or other immune compromised conditions

Treatment and study plan

Sinopsys Lacrimal Stent

Device

The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.

Other names: SLS

Primary outcomes

  1. SNOT - 20

    Time frame: 18 Weeks

    Chronic Rhinosinusitis symptoms as measured by SNOT-20 scores from baseline to 18 weeks follow-up (1, 4, 8, 12, and 18)

  2. Patency will be confirmed post procedure with passive flow through the SLS lumen by instilling 2-4 drops of sterile saline into the stented medial fornix and observing drainage.

    Time frame: 18 Weeks

    Patients will be trained for self-administration of saline irrigation prior to the discharge home. Subjects will be instructed how to observe for stent patency and to report problems with flow to the Investigator.

  3. Safety: Incidence and occurrence of anticipated and unanticipated adverse events

    Time frame: 18 Weeks

    Assessment of the incidence and occurrence of anticipated and unanticipated adverse events reported during the 18 weeks of the clinical study.

Secondary outcomes

  1. Lund-MacKay CT Scores

    Time frame: 12 Weeks

    Comparison of baseline and 12 weeks

  2. Lund-Kennedy Nasal Endoscopy Scores

    Time frame: 12 Weeks

    Comparison of baseline and 12 weeks

Sponsors and collaborators

Lead sponsor

Sinopsys Surgical

Industry

Registry information

Official study title

The Sinopsys Lacrimal Stent Indicated for Sinus Irrigation Via Transcaruncular Ethmoid Sinus Access in Patients With Moderate to Severe Chronic Rhinosinusitis With Ethmoid Sinus Involvement

Acronym: SLS

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Nov 21, 2014
Registry last updated
Feb 12, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.